Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.

IF 2.5 3区医学 Q1 OTORHINOLARYNGOLOGY

American Journal of Rhinology & Allergy Pub Date : 2025-03-01 Epub Date: 2025-01-09 DOI:10.1177/19458924241308953

Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa

{"title":"Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma.","authors":"Rijul S Kshirsagar, Jacob G Eide, Jacob Harris, Arash Abiri, Daniel M Beswick, Eugene H Chang, Nicholas Fung, Michelle Hong, Brian J Johnson, Michael A Kohanski, Christopher H Le, Jivianne T Lee, Seyed A Nabavizadeh, Isaac P Obermeyer, Vivek C Pandrangi, Carlos D Pinheiro-Neto, Timothy L Smith, Carl H Snyderman, Jeffrey D Suh, Eric W Wang, Marilene B Wang, Garret Choby, Mathew Geltzeiler, Jillian Lazor, Tara C Mitchell, Edward C Kuan, James N Palmer, Nithin D Adappa","doi":"10.1177/19458924241308953","DOIUrl":null,"url":null,"abstract":"Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":" ","pages":"102-108"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Rhinology & Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19458924241308953","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma.

Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma.

Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded.

Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT (n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab (n = 17, 32.7%) or pembrolizumab (n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively.

Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.

查看原文本刊更多论文

鼻黏膜黑色素瘤的免疫治疗效果。

背景：鼻黏膜黑色素瘤的生存率较差，尽管采用了多种治疗方法。虽然免疫治疗（IT）对转移性皮肤黑色素瘤的影响是明确的，但对鼻黏膜黑色素瘤的研究相对较少。目的：我们试图确定鼻粘膜黑色素瘤患者的免疫治疗结果。方法：一项回顾性队列研究评估了接受IT治疗的SNMM患者的总体治疗策略。记录患者人口统计、治疗和生存结果。结果：2000 - 2022年接受IT治疗的SNMM患者52例，平均年龄69.1±11.9岁。最常见的治疗方法是手术+放疗+ IT （n = 26,50%）。大多数方案由Nivolumab和Ipilimumab （n = 17, 32.7%）或pembrolizumab （n = 14, 26.9%）联合组成。44.2%的患者出现并发症。1年、2年和5年的总生存率分别为86.9%、74.1%和39.1%。结论：大约一半的患者在免疫治疗后会有局部反应，但在转移部位有改善是罕见的。我们小组的进一步研究将评估预测反应的最佳时间和标记。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Rhinology & Allergy 医学-耳鼻喉科学

CiteScore

5.60

自引率

11.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The American Journal of Rhinology & Allergy is a peer-reviewed, scientific publication committed to expanding knowledge and publishing the best clinical and basic research within the fields of Rhinology & Allergy. Its focus is to publish information which contributes to improved quality of care for patients with nasal and sinus disorders. Its primary readership consists of otolaryngologists, allergists, and plastic surgeons. Published material includes peer-reviewed original research, clinical trials, and review articles.